(NASDAQ: FATE) Fate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.91%.
Fate Therapeutics's earnings in 2025 is -$178,231,000.On average, 9 Wall Street analysts forecast FATE's earnings for 2025 to be -$188,939,309, with the lowest FATE earnings forecast at -$235,761,269, and the highest FATE earnings forecast at -$91,115,466. On average, 3 Wall Street analysts forecast FATE's earnings for 2026 to be -$130,602,632, with the lowest FATE earnings forecast at -$151,479,463, and the highest FATE earnings forecast at -$107,060,673.
In 2027, FATE is forecast to generate -$140,090,030 in earnings, with the lowest earnings forecast at -$140,090,030 and the highest earnings forecast at -$140,090,030.